Several treatments that target cancer cells via CD19 have either entered the market or are undergoing regulatory evaluation, including modified monoclonal antibodies against CD19 (e.g. tafasitamab) and chimeric antigen receptor (CAR) T-cell therapies (e.g. tisagenlecleucel). This evidence concerns the gene CD19 and cancer.